Potential of a glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes

Triagonists of GLP‐1R/ GIPR /GCGR, including SAR441255, bind to each receptor and induce specific effects through each receptor signaling pathway, thus result in weight loss and glycemic control in obese T2D animal models.[Image: see text]

Detalles Bibliográficos
Autores principales: Araki, Eiichi, Sakaguchi, Masaji, Fukuda, Kazuki, Kondo, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720191/
https://www.ncbi.nlm.nih.gov/pubmed/36039895
http://dx.doi.org/10.1111/jdi.13896
_version_ 1784843499459313664
author Araki, Eiichi
Sakaguchi, Masaji
Fukuda, Kazuki
Kondo, Tatsuya
author_facet Araki, Eiichi
Sakaguchi, Masaji
Fukuda, Kazuki
Kondo, Tatsuya
author_sort Araki, Eiichi
collection PubMed
description Triagonists of GLP‐1R/ GIPR /GCGR, including SAR441255, bind to each receptor and induce specific effects through each receptor signaling pathway, thus result in weight loss and glycemic control in obese T2D animal models.[Image: see text]
format Online
Article
Text
id pubmed-9720191
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97201912022-12-06 Potential of a glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes Araki, Eiichi Sakaguchi, Masaji Fukuda, Kazuki Kondo, Tatsuya J Diabetes Investig Commentary Triagonists of GLP‐1R/ GIPR /GCGR, including SAR441255, bind to each receptor and induce specific effects through each receptor signaling pathway, thus result in weight loss and glycemic control in obese T2D animal models.[Image: see text] John Wiley and Sons Inc. 2022-08-30 2022-12 /pmc/articles/PMC9720191/ /pubmed/36039895 http://dx.doi.org/10.1111/jdi.13896 Text en © 2022 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Commentary
Araki, Eiichi
Sakaguchi, Masaji
Fukuda, Kazuki
Kondo, Tatsuya
Potential of a glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes
title Potential of a glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes
title_full Potential of a glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes
title_fullStr Potential of a glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes
title_full_unstemmed Potential of a glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes
title_short Potential of a glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes
title_sort potential of a glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720191/
https://www.ncbi.nlm.nih.gov/pubmed/36039895
http://dx.doi.org/10.1111/jdi.13896
work_keys_str_mv AT arakieiichi potentialofaglucagonlikepeptide1receptorglucosedependentinsulinotropicpolypeptidereceptorglucagonreceptortriagonistforthetreatmentofobesityandtype2diabetes
AT sakaguchimasaji potentialofaglucagonlikepeptide1receptorglucosedependentinsulinotropicpolypeptidereceptorglucagonreceptortriagonistforthetreatmentofobesityandtype2diabetes
AT fukudakazuki potentialofaglucagonlikepeptide1receptorglucosedependentinsulinotropicpolypeptidereceptorglucagonreceptortriagonistforthetreatmentofobesityandtype2diabetes
AT kondotatsuya potentialofaglucagonlikepeptide1receptorglucosedependentinsulinotropicpolypeptidereceptorglucagonreceptortriagonistforthetreatmentofobesityandtype2diabetes

Ejemplares similares